会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • MENIGOCOCCUS VACCINE CONTAINING LIPOOLIGOSACCHARIDE (LOS) FROM MODIFIED STRAINS OF L6 IMMUNOTYPE NEISSERIA MENINGITIDIS
    • 含有L6寡糖的LIGOLIGOSACCHARIDE(LOS)来自L6免疫球蛋白的改良菌株
    • WO2010130898A3
    • 2010-12-29
    • PCT/FR2010000367
    • 2010-05-12
    • SANOFI PASTEURMISTRETTA NOELLEMOREAU MONIQUERENAULD-MONGENIE GENEVIEVEROKBI BACHRA
    • MISTRETTA NOELLEMOREAU MONIQUERENAULD-MONGENIE GENEVIEVEROKBI BACHRA
    • C12N1/21A61K39/095C12N15/63
    • A61K31/739A61K9/127A61K39/095
    • The invention particularly relates to multivalent vaccine compositions capable of treating or preventing at least 60% and preferably 75% of the infections caused by Neisseria meningitidis, in particular those of serogroup B. To this end, the invention substantially relates to lipooligosaccharide (LOS) of N. meningitidis particularly consisting of a lipid A, an inner core, and an L6 a chain, wherein the heptose II residue of the inner core has, at the O-3 position and at the O-6 or O-7 position, a phosphoethanolamine (PEA) substituent, as well as the structure of the N. meningitidis strain capable of expressing such LOS. The invention also relates to a strain of N. meningitidis of serogroup A that comprises lipooligosaccharide (LOS) particularly consisting of a lipid A, an inner core, and an L6 a chain, wherein the heptose II residue of the inner core has, at the O-3 position, a phosphoethanolamine (PEA) substituent and does not have any PEA substituent at the O-6 and O-7 positions. The abovementioned LOS or those from the mentioned strains can be used as vaccine antigens, in particular in multivalent, inter alia, bivalent, compositions in order to provide protection against major epidemiological complexes of N. meningitides, in particular of serogroup B.
    • 本发明特别涉及能够治疗或预防由脑膜炎奈瑟氏球菌,特别是血清组B引起的至少60%,优选75%的感染的多价疫苗组合物。为此,本发明基本上涉及脂多糖(LOS) 脑膜炎奈瑟球菌特别由脂质A,内核和L6链组成,其中内核的肝素II残基在O-3位置和O-6或O-7位具有 磷酸乙醇胺(PEA)取代基,以及能够表达这种LOS的脑膜炎奈瑟氏球菌菌株的结构。 本发明还涉及血清组A的脑膜炎奈瑟氏球菌菌株,其包含特别由脂质A,内核和L6链构成的脂寡糖(LOS),其中内核的肝脏II残基在 O-3位,磷酸乙醇胺(PEA)取代基,O-6和O-7位没有任何PEA取代基。 上述LOS或来自所述菌株的LOS可以用作疫苗抗原,特别是多价,特别是二价的组合物,以便提供防止脑膜炎奈瑟球菌,特别是血清群B的主要流行病学复合物的保护。
    • 4. 发明申请
    • POLYMYXIN B ANALOGS FOR LPS DETOXIFICATION
    • 多聚霉素B类似物用于LPS解毒
    • WO2006108586A3
    • 2006-12-14
    • PCT/EP2006003237
    • 2006-04-10
    • SANOFI PASTEURBIOSYNTH
    • PORRO MASSIMOKRELL TINOMISTRETTA NOELLEMOREAU MONIQUERUSTICI ALESSANDROVELUCCHI MASSIMO
    • C07K7/08A61K38/10A61K38/16C07K14/195
    • C07K7/06A61K47/62
    • The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulphide bonds involving the two cystein residues present in the peptide sequence, which does not exceed 17 amino acids and essentially comprises cationic and hydrophobic amino acid residues. In the dimers of the invention, peptides may have a parallel or anti-parallel orientation. As a matter of example, a dimer of the invention is constituted by a peptide of formula NH2-Lys-Thr-Lys-Cysl-Lys-Phe-Leu- Leu-Leu-Cys2-COOH, either in a parallel or antiparallel dimeric form. SAEP II dimers are useful for treating or preventing septic shock and related disorders generated by Gram-negative bacteria infection. The invention also relates to LPS-peptide complexes in which LPS and SAEP II dimers are non-covalently bound together. These complexes are useful as vaccinal agents against Gram-negative bacteria infection.
    • 本发明涉及模拟多粘菌素B i.a.的SAEP II肽二聚体。 其能够非共价结合革兰氏阴性细菌的脂多糖(LPS)并具有高亲和力,因此可以像多粘菌素B那样将LPS解毒。 二聚体结构由涉及肽序列中存在的两个半胱氨酸残基的一对二硫键维持,其不超过17个氨基酸且主要包含阳离子和疏水性氨基酸残基。 在本发明的二聚体中,肽可以具有平行或反平行的取向。 作为例子,本发明的二聚体由式NH 2 -Lys-Thr-Lys-Cysl-Lys-Phe-Leu-Leu-Leu-Cys 2 -COOH的肽以平行或反平行二聚体形式 。 SAEP II二聚体可用于治疗或预防由革兰氏阴性菌感染产生的感染性休克和相关疾病。 本发明还涉及其中LPS和SAEP II二聚体非共价结合在一起的LPS-肽复合物。 这些复合物可用作抗革兰氏阴性菌感染的疫苗。